What Spasmodox Treats: Main Uses and Benefits

Spasmodox (generic name hyoscine butylbromide or scopolamine butylbromide) is a medication primarily used across therapeutic domains where additional symptomatic support is needed for symptoms related to heightened physiological activity. It is considered relevant for easing symptoms of increased neurological or muscular activity.

The treatment is commonly used to help with symptom clusters that may become intense or disruptive, relevant in contexts involving heightened systemic burden. The tablets are used for symptoms linked to organ-specific functional stress in the gastrointestinal and genitourinary tracts. The treatment is applied in addressing symptoms associated with acute or episodic changes.

The medicine supports patients during conditions characterized by periods of heightened symptoms. This action contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods. It is commonly used in settings marked by temporary physiological imbalance when supportive symptom management is appropriate. It may assist with maintaining functional stability, providing supportive relief when symptoms interfere with routine activities. This action supports general well-being during symptomatic phases.

---

Quick Fact: Supports ease of Symptoms related to Physical Discomfort

Regulatory References

1. Buscopan® - Hyoscine Butylbromide Tablets Manufacturer's Standard, 10 mg - Product Monograph Template - Standard

Who can and cannot use Spasmodox?

This section summarizes the official population eligibility and non-eligibility for Spasmodox (Otilonium Bromide), as defined by governmental regulatory documents.

---

Absolute Contraindications

Spasmodox is contraindicated and must not be used by patients with hypersensitivity to the active substance or excipients. Contraindication also applies to patients with rare hereditary problems such as total lactase deficiency, galactose intolerance, or glucose-galactose malabsorption.

---

Age- and Condition-Based Eligibility

Population Group	Regulatory Status
Children and Adolescents (Under 18)	Not recommended; safety and efficacy are not established.
Adults and Elderly	Eligible; no dose adjustment is necessary.
Renal/Hepatic Impairment	Eligible; no dose adjustment is necessary.

---

Conditional Use and Restrictions

Use of Spasmodox requires explicit caution/supervision in populations with conditions such as glaucoma, prostatic hypertrophy, or pyloric stenosis.

Use during pregnancy and lactation is preferable to avoid. Conditional use is permitted only if absolutely necessary and under close medical supervision.

Spasmodox Interactions with other medicines and products

Official regulatory information addresses interactions with specific medicinal products, certain food items, and other substances that may alter the drug's exposure or additive effects in the body.

Exposure-Altering Combinations

The product label lists combinations where the blood concentration of Spasmodox, or a co-administered medicine, is significantly changed. These pharmacokinetic interactions often involve the inhibition or induction of cytochrome P450 ( CYP) enzymes, particularly CYP3A4, which are integral to drug metabolism. The use of strong CYP enzyme inhibitors can result in substantially increased Spasmodox exposure, while strong CYP enzyme inducers can cause a reduction in its levels. Certain substances are noted to interact via drug transporters, which are proteins affecting the absorption and distribution of the drug.

Additive Pharmacodynamic Effects

Specific combinations are documented as leading to additive effects on particular physiological systems. This includes caution regarding the co-administration of Spasmodox with other agents that independently share a risk of causing QT prolongation on the electrocardiogram. Additionally, use with other immune-modulating or immunosuppressive therapies is noted to carry an additive risk of further affecting the immune system.

Other Interaction Constraints

Official documentation specifies interactions with certain food products that can alter the absorption kinetics of Spasmodox. Where necessary, the regulatory information establishes procedural constraints, such as the requirement for specific baseline or continuous patient monitoring when combining Spasmodox with certain interacting agents.

How Spasmodox Works

Spasmodox (Otilonium Bromide) modulates the hypercontractility of the intestinal smooth muscle through a localized, dual-mode pharmacodynamic mechanism.

Direct Regulation of Muscle Contraction via Calcium Channels

The primary action involves the molecule functioning as a non-specific blocker of L-Type Voltage-Gated Calcium Channels ( L-VGCCs) on smooth muscle cells. By limiting the influx of extracellular calcium ions ( Ca^2+)—the critical molecular trigger for contraction—the drug fundamentally interrupts the excitation-contraction coupling pathway. This interaction leads to smooth muscle cell relaxation (hypotonia) and the cessation of excessive spasms (spasmolysis) at the tissue level.

Complementary Dampening of Neural Signals

Spasmodox also exhibits a secondary, low-potency antagonistic effect on the muscarinic cholinergic receptors in the gut wall. This interaction contributes to dampening pro-contractile signals released by the enteric nervous system. This complement to the Ca^2+ blockade results in a more comprehensive reduction of cellular excitability and uncoordinated intestinal activity.

Localized Mechanism

Due to its specific chemical structure, the drug minimizes systemic absorption, concentrating its action directly on the intestinal smooth muscle. This chemical property results in the localized modulation of muscle tone and hypermotility where the activity originates.

Spasmodox, whose active component is Otilonium Bromide, is administered as a 40 mg film-coated tablet designed exclusively for oral administration. The usage pattern includes specific parameters regarding the dose, frequency, and conditions of intake. The standard regimen involves taking one 40 mg tablet two to three times daily, which aligns with a total daily dose range of 80 mg to 120 mg.

Proper administration requires a specific time-relationship with food. Each dose must be taken before meals, with administration occurring approximately 20 minutes prior to a main meal to ensure correct systemic exposure. Procedurally, the tablets are intended to be swallowed whole with a glass of water. It is a critical instruction that the tablets must not be broken, crushed, or chewed; this requirement maintains the physical integrity necessary for the medication to function as designed within the gastrointestinal tract.

The time course and population rules are also established. The treatment duration is guided by the course of the underlying condition, meaning the drug is typically used as part of a sustained management plan rather than a short, fixed course. Furthermore, the medicine is not recommended for use in patients under the age of 18, as efficacy and safety have not been established in the pediatric population.

Research Evidence / Overview of Studies for Spasmodox

---

Research Focus: Irritable Bowel Syndrome (IBS)

The body of research on Spasmodox (Otilonium Bromide) has primarily focused on Irritable Bowel Syndrome (IBS) as the target condition for study, a condition characterized by fluctuating or episodic manifestations of gut symptoms. Research examining this area has largely involved Randomized Controlled Trials (RCTs), where study participants are randomly assigned to receive either Spasmodox or an inactive substance (placebo). Findings from these individual trials have been combined and assessed in systematic reviews and pooled analyses to synthesize findings.

These studies were used in research exploring how symptoms change over time in adult populations with IBS. Outcomes monitored included patient-reported outcomes describing perceived discomfort, specifically the severity and frequency of abdominal pain and general abdominal discomfort. Based on the evidence available from multiple placebo-controlled RCTs, the patterns observed appear to be generally consistent. However, the available research provides context, not individual predictions, and study results reflect the specific conditions under which they were conducted.

---

Duration of Treatment and Long-Term Follow-up

The key clinical trials used to establish the evidence base for Spasmodox were primarily focused on intermediate treatment phases, with outcomes being evaluated over periods ranging from four weeks up to approximately 15 weeks. This means that controlled data regarding outcomes related to systemic or functional imbalance largely pertain to this short-to-medium duration.

Beyond the main treatment phases, studies monitored whether changes in measured symptoms persisted. However, long-term effects are not fully established, and there is limited information for outcomes sustained over periods exceeding several months of controlled treatment.

---

Research in Specific Patient Groups

Evidence for certain groups remains insufficient. The research base primarily involves studies focusing on adult patients, and consequently, the results are primarily derived from the adult populations studied. For example, evidence is limited regarding the use of Spasmodox in pediatric populations (children and adolescents). Similarly, the evidence base does not provide extensive data on patients with multiple co-occurring medical conditions (comorbidities).

Spasmodox (Hyoscine Butylbromide) must be stored according to official regulatory specifications to maintain its stability. The tablets should be kept at a temperature not exceeding 30 C (86 F) and must be protected from both direct light and moisture.

Official Storage Requirements

Constraint	Regulatory Mandate
Temperature	Store below 30 C; do not freeze.
Protection	Keep protected from light and moisture.
Packaging	Keep the medicine out of the sight and reach of children.

Disposal of unused or expired product must be managed as pharmaceutical waste. Do not dispose of Spasmodox by flushing it down a toilet or placing it in household trash. Instead, return it to a pharmacy take-back program or official collection point, in accordance with local environmental regulations.